


MAP4K2 TE Assay

| | | <u>Naterials Needed</u> |
|-------------------|-------------------|---|
| Assay Format: | NBS (1) | |
| NanoBRET™ Tracer: | K-5 (2) | NanoLuc[®]-MAP4K2 Fusion Vector (Cat.# NV1621) |
| 100X [Tracer]: | 100μM in DMSO | Transfection Carrier DNA (kit component; 2) |
| Final [Tracer]: | 1μΜ | |
| Assay Category: | Medium Window (3) | NanoBRET [™] TE Intracellular Kinase Assay, K-5 (Cat.# |
| Z': | 0.90 | N2500, N2501, or N2530; 2) |
| | | |
| | | |

Mataviala Nacalad



NanoLuc-MAP4K2 Tracer Affinity NanoLuc-MAP4K2 Compound Affinity 10 20-[Tracer] Tracer Only BRET Ratio (mBu) -₩ 2μM 8 Tracer + excess **BRET Ratio (mBu)** 🔺 1μΜ 15 unlabeled 6 - 0.5μM 4 ↔ 0.25µM 10 ↔ 0.13µM 2- $EC_{50} > 1 \mu M$ 5 0-10-4 10-2 100 10² [Test Compound], µM 0-10⁻³ **10**⁻¹ 10-2 10° 0.25µM $2\mu M$ $1 \mu M$ 0.5µM 0.13µM [NanoBRET[™] Tracer K-5], µM IC50 0.29 0.25 0.22 0.15 0.25

Example NanoBRET™ Tracer K-5 data in HEK293 cells transiently expressing NanoLuc®-MAP4K2

Top Panel: Overview of the NanoBRET[™] TE Assay. **Other Panels:** HEK293 cells were first transfected with NanoLuc[®]-MAP4K2 Fusion Vector and Transfection Carrier DNA (1 to 9 transfection ratio) and then were subsequently resuspended in OptiMEM prior to seeding into 96-well plates: **Bottom Left Panel:** Tracer affinity was measured by treating the cells with increasing concentrations of tracer in the presence or absence of a molar excess of unlabeled compound. **Bottom Right Panel:** The apparent cellular affinity of the unlabeled compound was measured at multiple fixed concentrations of the tracer, where the IC₅₀ at the recommended tracer concentration is depicted in **orange** (4).





Notes:

- (1) This assay is run in the non-binding surface format. See the NanoBRET[™] TE Intracellular Kinase Assay, Non-Binding Surface Format Technical Manual (#TM603) for protocol details.
- (2) NanoBRET[™] Tracer K-5 is supplied within the NanoBRET[™] TE Intracellular Kinase Assay, K-5 products (N2500, N2501, or N2530). Additional assay components are supplied within these kits, including the NanoBRET[™] Nano-Glo[®] Substrate, Extracellular NanoLuc[®] Inhibitor, and TE Tracer Dilution Buffer. Additionally, BTK-NanoLuc[®] Fusion Vector (as a control) and Transfection Carrier DNA are provided in products N2500 and N2501. Transfection carrier DNA products (E4881 and E4882) are also available separately. For full details, please see the Promega website or technical manual for these products.
- (3) Assay category is defined by the assay window at the recommended tracer concentration. It is detailed in section 7.A within the NanoBRET[™] TE Intracellular Kinase Assay, Non-Binding Surface Format Technical Manual (#TM603).
- (4) See section 5 of NanoBRET[™] TE Intracellular Kinase Assay, Non-Binding Surface Format Technical Manual (#TM603) regarding approaches to achieve quantitative analysis of test compound affinity.
- (5) NanoBRET[™] TE Intracellular Assays have also been applied to Residence Time analysis. For a kinase example, please refer to Forster, M. *et al.* For an HDAC example please refer to Robers, M.B. *et al.*

References:

Vasta, J. D. *et al.* (2018) Quantitative, wide-spectrum kinase profiling in live cells for assessing the effect of cellular ATP on target engagement. *Cell Chem. Biol.* **25**, 206.

Robers, M.B. *et al.* (2015) Target engagement and drug residence time can be observed in living cells with BRET. *Nature Comm.* **6**, 10091.

Forster, M. *et al.* (2016) Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. *Cell Chem. Biol.* **23**, 1335.

This protocol was developed by Promega Scientists and is intended for research use only.

Users are responsible for determining suitability of the protocol for their application.

Further information can be found in Technical Manual #TM603, available at: www.promega.com/protocols